世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

北米の肺がん検診市場の2030年までの予測 がんタイプ別［非小細胞肺がん（NSCLC）、小細胞肺がん］、技術別［低線量コンピュータ断層撮影（LDCT）、胸部X線、リキッドバイオプシー、その他］、年齢層別（50歳以上、50歳未満）、エンドユーザー別（病院、診断センター、その他）の地域別分析


North America Lung Cancer Screening Market Forecast to 2030 Regional Analysis by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

北米の肺がん検診市場は、2022年の9億6,541万米ドルから2030年には18億1,148万米ドルに成長すると予測されている。2022年から2030年までの年平均成長率は8.2%と推定される。 政府支援の増加が北米肺がん検診市場... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
The Insight Partners
ザ・インサイトパートナーズ 		2023年11月7日 US$3,000
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		100 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

北米の肺がん検診市場は、2022年の9億6,541万米ドルから2030年には18億1,148万米ドルに成長すると予測されている。2022年から2030年までの年平均成長率は8.2%と推定される。
政府支援の増加が北米肺がん検診市場を後押し

肺がんは、世界全体の主要な死亡原因のひとつである。肺がん検診は、がん予防アプローチの重要な要素である。肺がん患者の予後は、早期に診断された場合に良好であるため、肺がんのリスクが高い人は、肺にがんができるのを発見するために定期的な検査を受けることが奨励されている。米国癌協会による2023年の米国における肺癌の推計によると、約238,340人の肺癌患者が新たに登録され、そのうち女性では120,790人、男性では117,550人が報告されている。このように、世界的な肺がん罹患率の上昇が肺がん検診プログラムの開始に寄与しており、これが市場の成長を牽引している。

北米肺がん検診市場概要

北米の肺がん検診市場は、米国、カナダ、メキシコに区分される。この地域の成長は、肺がんの罹患率の増加や喫煙の副作用に対する人々の認識など、さまざまな要因によるものです。また、検診に対する政府支援の高まりが市場のさらなる成長につながっている。

北米では、米国が北米肺がん検診市場で大きなシェアを占めている。この国の市場成長は、主に肺がんの罹患率の増加と政府のイニシアチブによってもたらされている。肺がんは、米国では男女ともに2番目に多いがんである。米国癌協会（American Cancer Society, Inc.）によると、2023年現在、米国の成人約238,340人（男性117,550人、女性120,790人）が肺癌と診断され、〜127,070人（男性67,160人、女性59,910人）が肺癌が原因で死亡している。肺癌は全癌死亡の5人に1人を占め、米国における癌死亡の主要原因となっている。この統計には小細胞肺癌とNSCLCの両方が含まれる。NSCLCは最も一般的な肺癌のタイプで、肺癌診断全体の81％を占める。米国の全肺癌の5年相対生存率は23％で、NSCLCの5年相対生存率は男性23％、女性33％である。米国では、低線量ヘリカルまたはスパイラルCT（CTまたはCAT）スキャンと呼ばれる検査による肺癌スクリーニングが推奨されている。予防サービス専門委員会（USPSTF）は、50～80歳で喫煙歴が20箱年以上ある人、または過去15年以内に禁煙した人は、毎年低線量CTスキャンによる肺がん検診を受けることを推奨している。2023年5月、デジタル戦略室が管理するホワイトハウスの公式ウェブサイトwhitehouse.govに掲載された報告書によると、地域がんセンター協会（ACCC）とアストラゼネカは、"アパラチア地方肺がん検診イニシアチブ "を通じて、アメリカの地方における肺がん検診を増加させるために、人を中心とした持続可能なアプローチを開発し、実施するためのパートナーシップを締結する。アパラチア地方（ウェストバージニア州全域と他の12州の一部を含む）のがん死亡率は、米国の他の地域よりも10％高い。このイニシアチブの目的は、肺がんの5年生存率を2倍にすることである。このような取り組みが、米国における北米肺がん検診市場の成長に寄与している。

北米肺がん検診市場の売上高と2030年までの予測 (百万米ドル)

北米肺がん検診市場のセグメンテーション

北米の肺がんスクリーニング市場は、がん種、技術、年齢層、エンドユーザー、国別に区分される。

癌の種類に基づき、北米の肺癌スクリーニング市場は非小細胞肺癌（NSCLC）、小細胞肺癌に区分される。2022年の北米肺がんスクリーニング市場では、非小細胞肺がん（NSCLC）セグメントが大きなシェアを占めている。

技術に基づき、北米肺がんスクリーニング市場は胸部X線、低線量コンピュータ断層撮影（LDCT）、リキッドバイオプシー、その他に区分される。低線量コンピュータ断層撮影（LDCT）セグメントが2022年の北米肺がんスクリーニング市場で最大のシェアを占めた。

年齢層に基づき、北米の肺がん検診市場は50歳以上と50歳未満に区分される。50歳以上のセグメントが2022年の北米肺がん検診市場で大きなシェアを占めた。

エンドユーザーに基づき、北米肺がんスクリーニング市場は病院、診断センター、その他に区分される。病院セグメントが2022年の北米肺がん検診市場で最大のシェアを占めた。

国別では、北米肺がんスクリーニング市場は米国、カナダ、メキシコに区分される。2022年の北米肺がん検診市場は米国が支配的であった。
Siemens AG、Koninklijke Philips NV、Canon Inc、Medtronic、GE HealthCare、Nuance Communications Inc、LungLife AI、Inc、Intelerad Medical Systems、bioAffinity Technologies、Inc、CSV Healthは、北米肺がんスクリーニング市場で事業を展開する主要企業の一部である。

ページTOPに戻る


目次

Table of Contents

1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Lung Cancer Screening Market – by Technology
1.3.2 North America Lung Cancer Screening Market – by Cancer Type
1.3.3 North America Lung Cancer Screening Market – by Age Group
1.3.4 North America Lung Cancer Screening Market – by End User
1.3.5 North America Lung Cancer Screening Market – by Country
2. North America Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Lung Cancer Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Lung Cancer Incidences
5.1.2 Increasing Government Support
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Use of Cutting-Edge Technologies
5.5 Impact Analysis
6. Lung Cancer Screening Market – North America Analysis
6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis
7. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – By Cancer Type
7.1 Overview
7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
8.2.1 Overview
8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
8.3.1 Overview
8.3.2 Chest X-ray: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
8.4.1 Overview
8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
9. North America Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 & Older
9.2.1 Overview
9.2.2 & Older: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
9.3.1 Overview
9.3.2 Below 50: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Hospitals
10.2.1 Overview
10.2.2 Hospitals: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – Country Analysis
11.1 North America Lung Cancer Screening Market Overview
11.1.1.1 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.3 US: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.1.4 US: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.5 US: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.1.6 US: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.3 Canada: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.2.4 Canada: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.5 Canada: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.2.6 Canada: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.3 Mexico: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.3.4 Mexico: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.5 Mexico: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.3.6 Mexico: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
12. North America Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CVS Health
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 LungLife AI, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms

　

ページTOPに戻る


　

Summary

The North America lung cancer screening market is expected to grow from US$ 965.41 million in 2022 to US$ 1,811.48 million by 2030. It is estimated to grow at a CAGR of 8.2% from 2022 to 2030.
Increasing Government Support Fuel North America lung cancer screening market.

Lung cancer is among the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis for lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are encouraged to undergo routine testing to detect the formation of cancerous growth in their lungs. According to estimates by the American Cancer Society for lung cancer in the US for 2023, about 238,340 new lung cancer cases were registered; of these, 120,790 in women and 117,550 in men were reported. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

North America Lung Cancer Screening Market Overview

The North America, Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side effects of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

In North America, the US holds a significant share of the North America Lung Cancer Screening Market . The market growth in this country is primarily driven by the increasing incidence of lung cancer and government initiatives. Lung cancer is the second most common cancer in both men and women in the US. As per the American Cancer Society, Inc., as of 2023, approximately 238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer, and ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung Cancer accounts for 1 in 5 of all cancer death, making it a leading cause of cancer death in the US. These statistics include both small cell lung cancer and NSCLC. NSCLC is the most common type of lung cancer, accounting for 81% of all lung cancer diagnoses. For all types of lung cancer in the US, the 5-year relative survival rate is 23%, and for NSCLC, the 5-year relative survival rate for men and women is 23% and 33%, respectively. In the US, screening for lung cancer is recommended with a test called a low-dose helical or spiral computed tomography (CT or CAT) scan. Preventive Services Task Force (USPSTF) recommends that people aged 50–80, with a history of smoking 20 pack years or more, or who have quit within the past 15 years should go through screening for lung cancer with low-dose CT scans each year. As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca are entering into a partnership to develop and implement person-centered and sustainable approaches to increase lung cancer screening in rural America through the “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and parts of 12 other states, is 10% higher than that in the rest of the US. The aim of this initiative is to double the five-year survival rate for lung cancer. Such initiatives are contributing to the North America Lung Cancer Screening Market growth in the US.

North America Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

North America Lung Cancer Screening Market Segmentation

The North America lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the North America lung cancer screening market is segmented into non–small cell lung cancer (NSCLC), and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the North America lung cancer screening market in 2022.

Based on technology, the North America lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the North America lung cancer screening market in 2022.

Based on age group, the North America lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the North America lung cancer screening market in 2022.

Based on end user, the North America lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the North America lung cancer screening market in 2022.

Based on country, the North America Lung Cancer Screening Market is segmented into the US, Canada, and Mexico. The US dominated the North America lung cancer screening market in 2022.
Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, LungLife AI, Inc, Intelerad Medical Systems, bioAffinity Technologies, Inc, and CSV Health are some of the leading companies operating in the North America lung cancer screening market.



ページTOPに戻る


Table of Contents

Table of Contents

1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Lung Cancer Screening Market – by Technology
1.3.2 North America Lung Cancer Screening Market – by Cancer Type
1.3.3 North America Lung Cancer Screening Market – by Age Group
1.3.4 North America Lung Cancer Screening Market – by End User
1.3.5 North America Lung Cancer Screening Market – by Country
2. North America Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Expert’s Opinion
5. North America Lung Cancer Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Lung Cancer Incidences
5.1.2 Increasing Government Support
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Use of Cutting-Edge Technologies
5.5 Impact Analysis
6. Lung Cancer Screening Market – North America Analysis
6.1 North America Lung Cancer Screening Market Revenue Forecast and Analysis
7. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – By Cancer Type
7.1 Overview
7.2 North America Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–Small Cell Lung Cancer (NSCLC): North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
8. North America Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
8.2.1 Overview
8.2.2 Low-Dose Computed Tomography (LDCT): North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
8.3.1 Overview
8.3.2 Chest X-ray: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
8.4.1 Overview
8.4.2 Liquid Biopsy: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: North America Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
9. North America Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 & Older
9.2.1 Overview
9.2.2 & Older: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
9.3.1 Overview
9.3.2 Below 50: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10. North America Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Hospitals
10.2.1 Overview
10.2.2 Hospitals: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: North America Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
11. North America Lung Cancer Screening Market – Revenue and Forecast to 2028 – Country Analysis
11.1 North America Lung Cancer Screening Market Overview
11.1.1.1 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 US: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.3 US: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.1.4 US: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.5 US: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.1.6 US: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.3 Canada: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.2.4 Canada: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.5 Canada: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.2.6 Canada: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.3 Mexico: North America Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.3.4 Mexico: North America Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.5 Mexico: North America Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.3.6 Mexico: North America Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
12. North America Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 CVS Health
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 bioAffinity Technologies, Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 LungLife AI, Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

The Insight Partners社の医療機器分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


The Insight Partners社はどのような調査会社ですか?


The Insight Partnersはインドに本社を置く調査会社です。経験豊富な専門家チームを通じて、お客様に最適な調査と分析を提供することに専念しています。幅広い分野をカバーしていますがヘルスケ... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/19　10:26

155.94 円

162.31 円

199.02 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.